Regulatory News: POXEL SA (Euronext : POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious …
LYON, France–(BUSINESS WIRE)–Regulatory News:
POXEL SA (Euronext : POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic d… [11441 chars]
Source: Business Wire | Published: 2025-11-05T07:58:00Z
Credit: Business Wire
